This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Minotti, G. Articles by Cairo, G. Search for Related Content PubMed PubMed Citation Articles by Minotti, G. Articles by Cairo, G.

Doxorubicin Irreversibly Inactivates Iron Regulatory Proteins 1 and 2 in Cardiomyocytes

Evidence for Distinct Metabolic Pathways and Implications for Iron-mediated Cardiotoxicity of Antitumor Therapy¹

Department of Drug Sciences, G. D’Annunzio University School of Pharmacy, 66013 Chieti [G. M., E. S., P. M.], and Institute of General Pathology-Consiglio Nazionale delle Ricerche Center for Cell Pathology, University of Milan School of Medicine, 20133 Milan [R. R., G. C.], Italy

Changes in iron homeostasis have been implicated in cardiotoxicity induced by the anticancer anthracycline doxorubicin (DOX). Certain products of DOX metabolism, like the secondary alcohol doxorubicinol (DOXol) or reactive oxygen species (ROS), may contribute to cardiotoxicity by inactivating iron regulatory proteins (IRP) that modulate the fate of mRNAs for transferrin receptor and ferritin. It is important to know whether DOXol and ROS act by independent or combined mechanisms. Therefore, we monitored IRP activities in H9c2 rat embryo cardiomyocytes exposed to DOX or to analogues which were selected to achieve a higher formation of secondary alcohol metabolite (daunorubicin), a concomitant increase of alcohol metabolite and decrease of ROS (5-iminodaunorubicin), or a defective conversion to alcohol metabolite (mitoxantrone). On the basis of such multiple comparisons, we characterized that DOXol was able to remove iron from the catalytic Fe-S cluster of cytoplasmic aconitase, making this enzyme switch to the cluster-free IRP-1. ROS were not involved in this step, but they converted the IRP-1 produced by DOXol into a null protein which did not bind to mRNA, nor was it able to switch back to aconitase. DOX was also shown to inactivate IRP-2, which does not assemble or disassemble a Fe-S cluster. Comparisons between DOX and the analogues revealed that IRP-2 was inactivated only by ROS. Thus, DOX can inactivate both IRP through a sequential action of DOXol and ROS on IRP-1 or an independent action of ROS on IRP-2. This information serves guidelines for designing anthracyclines that spare iron homeostasis and induce less severe cardiotoxicity.

This article has been cited by other articles:

				X. Xu, R. Sutak, and D. R. Richardson Iron Chelation by Clinically Relevant Anthracyclines: Alteration in Expression of Iron-Regulated Genes and Atypical Changes in Intracellular Iron Distribution and Trafficking Mol. Pharmacol., March 1, 2008; 73(3): 833 - 844. [Abstract] [Full Text] [PDF]

				S. Turakhia, C. D. Venkatakrishnan, K. Dunsmore, H. Wong, P. Kuppusamy, J. L. Zweier, and G. Ilangovan Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27 Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3111 - H3121. [Abstract] [Full Text] [PDF]

				Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues Mol. Interv., June 1, 2007; 7(3): 147 - 156. [Abstract] [Full Text] [PDF]

				H.-R. Lu, H. Zhu, M. Huang, Y. Chen, Y.-J. Cai, Z.-H. Miao, J.-S. Zhang, and J. Ding Reactive Oxygen Species Elicit Apoptosis by Concurrently Disrupting Topoisomerase II and DNA-Dependent Protein Kinase Mol. Pharmacol., October 1, 2005; 68(4): 983 - 994. [Abstract] [Full Text] [PDF]

				A. Alberghini, S. Recalcati, L. Tacchini, P. Santambrogio, A. Campanella, and G. Cairo Loss of the von Hippel Lindau Tumor Suppressor Disrupts Iron Homeostasis in Renal Carcinoma Cells J. Biol. Chem., August 26, 2005; 280(34): 30120 - 30128. [Abstract] [Full Text] [PDF]

				X. Xu, H. L. Persson, and D. R. Richardson Molecular Pharmacology of the Interaction of Anthracyclines with Iron Mol. Pharmacol., August 1, 2005; 68(2): 261 - 271. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				T. L'Ecuyer, Z. Allebban, R. Thomas, and R. Vander Heide Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2057 - H2064. [Abstract] [Full Text] [PDF]

				G. Corna, P. Santambrogio, G. Minotti, and G. Cairo Doxorubicin Paradoxically Protects Cardiomyocytes against Iron-mediated Toxicity: ROLE OF REACTIVE OXYGEN SPECIES AND FERRITIN J. Biol. Chem., April 2, 2004; 279(14): 13738 - 13745. [Abstract] [Full Text] [PDF]

				S. FOGLI, P. NIERI, and M. C. BRESCHI The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage FASEB J, April 1, 2004; 18(6): 664 - 675. [Abstract] [Full Text] [PDF]

				A. Cartoni, P. Menna, E. Salvatorelli, D. Braghiroli, R. Giampietro, F. Animati, A. Urbani, P. Del Boccio, and G. Minotti Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids: NOVEL FUNCTION FOR FERRYLMYOGLOBIN J. Biol. Chem., February 13, 2004; 279(7): 5088 - 5099. [Abstract] [Full Text] [PDF]

				C. J. Miranda, H. Makui, R. J. Soares, M. Bilodeau, J. Mui, H. Vali, R. Bertrand, N. C. Andrews, and M. M. Santos Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin Blood, October 1, 2003; 102(7): 2574 - 2580. [Abstract] [Full Text] [PDF]

				M. Maiorino, M. Scapin, F. Ursini, M. Biasolo, V. Bosello, and L. Flohe Distinct Promoters Determine Alternative Transcription of gpx-4 into Phospholipid-Hydroperoxide Glutathione Peroxidase Variants J. Biol. Chem., September 5, 2003; 278(36): 34286 - 34290. [Abstract] [Full Text] [PDF]

				J. C. Kwok and D. R. Richardson Anthracyclines Induce Accumulation of Iron in Ferritin in Myocardial and Neoplastic Cells: Inhibition of the Ferritin Iron Mobilization Pathway Mol. Pharmacol., April 1, 2003; 63(4): 849 - 861. [Abstract] [Full Text] [PDF]

				J. C. Kwok and D. R. Richardson Unexpected Anthracycline-Mediated Alterations in Iron-Regulatory Protein-RNA-Binding Activity: The Iron and Copper Complexes of Anthracyclines Decrease RNA-Binding Activity Mol. Pharmacol., October 1, 2002; 62(4): 888 - 900. [Abstract] [Full Text] [PDF]

				S. Kotamraju, C. R. Chitambar, S. V. Kalivendi, J. Joseph, and B. Kalyanaraman Transferrin Receptor-dependent Iron Uptake Is Responsible for Doxorubicin-mediated Apoptosis in Endothelial Cells. ROLE OF OXIDANT-INDUCED IRON SIGNALING IN APOPTOSIS J. Biol. Chem., May 3, 2002; 277(19): 17179 - 17187. [Abstract] [Full Text] [PDF]